You are here: About SCNP / Constitution
Saturday, 25.05.2013

Statutes of SCNP

SCANDINAVIAN COLLEGE OF NEURO-PSYCHOPHARMACOLOGY

 

STATUTES 

 Originally adopted at the General Assembly on the 12th March 1964.

Statutes amended on 10th March 1972, 16th March 1973, 16th March 1984, 11th April 1991, 5th April 2000 and 18th April 2001  

 

§  1  The name of the Society is Scandinavian College of Neuro-Psychopharmacology (SCNP). The registered office is the official address of the SCNP Secretariat.

§  2  The objective of the Society is to promote Scandinavian neuro-psychopharmacological research.

§  3  Ordinary Membership of the Society can be obtained by researchers and clinicians from the Nordic Countries i.e. pharmacologists, pharmacists, physiologists, chemists, psychologists, psychiatrists, neurologists  or other clinicians  who are working with neuro-psychopharmacological research or have demonstrated a special interest for this research discipline.
New members should be proposed by 1 senior member of the Society and recommended for membership.
Extraordinary membership can be obtained by Pharmaceutical Companies, which are entitled to be represented at the Annual Meetings of the Society by 4 participants having the same advantages as Ordinary Members. In addition, members from the Pharmaceutical Industry have the opportunity to arrange an exhibition, a satellite symposium or other similar activities following  separate agreement.
Foreign Corresponding Members. Non-Nordic Researchers and clinicians of high scientific reputation can be especially appointed by the Board as Foreign Corresponding Members of the Society, the appointment being a special honour for the Foreign Corresponding Member in question.

The board of the Society exists of 8 members  representing  both basic research- and clinical science. The Board is constituted with 1 member from each of the Nordic countries with the exception of 2 members from the country representing the largest number of Ordinary Members and in addition with 1 member from the pharmaceutical companies  and the previous chairman (Past President). 

§  4  Election of Board Members takes place at the Annual General Assembly. The representatives from each country are separately elected. All members present at the General Assembly have the right to vote.
Board Members are elected for  a period of 3 years, however, with the option to be reelected for an extra period, i.e. a total period of service of 6 years. At each General Assembly only 4 members of the board can be on election. Among the Board Members elected  the General Assembly constitutes a Chairman/ President of the Society. The President is elected for a period of 3 years, and can be reelected for a period of 3 years. 

All  votes are decided by simple majority. 

Apart from the election of the President the Board constitutes itself and establishes new committees. The Board can dissolve committees established by the Board itself. 

§  5  The General Assembly is taking place each year during March  or April at the SCNP Annual Meeting and notice is forwarded to the members of the Society during January/February. The agenda of the General Assembly must include the following items:

1.        Election of Chairperson

2.        Procedural questions

3.        Report from the President

4.        Report from the treasurer and auditors report

5.        Discharge of obligations for the board

6.        Election of board members and chairman if actual

7.        Report from the SCNP committee(s) constituted by the General Assembly

8.        Venue and date for the coming SCNP Annual Meeting

9.        Membership fee for next year

10.     Other business

With the notice for the General Assembly, the board announces which board members who are on election and which candidates are proposed by the Board. All members of the Society can make proposals for new board members. Such proposals should be received by the Board no later than one month prior to the time of the General Assembly. 

At the General Assembly all members has the right to vote- and to make proposals. Each pharmaceutical company which holds an extraordinary  membership is entitled to have one vote.

The General Assembly may be extraordinarily summoned if such decision is made by the General Assembly or if 25% of the members are requesting such summond with a justified agenda. An extraordinary General Assembly can be summoned with no less than 1 day- and no further than 28 days of notice. 

§  6  The annual accounts of the Society are presented at the annual General Assembly. The annual accounts are submitted to the members no later than 14 days prior to the General Assembly. The accounts are audited by a Chartered  Accountant.

§  7  The membership fee is proposed by the board at the annual General Assembly.

§  8  The board can decide to contribute with economical support to travel- and other expenses to scientific meetings for members of the Society and can as well support research projects and publication of  such projects for  members of the Socierty.

§  9  The President and Secretary of the Society manage the activities of the Society and run all these activities through the administrative secretariat of the Society including correspondance and contact to the members. The administrative secretariat is getting paid by fees according to separate agreement with the Society.

§ 10  The statutes of the Society can be changed, if more than 2/3  of the votes at the General Assembly decides so. Proposals for such changes must be forwarded to the Board no later than one month prior to the General Assembly and must be forwarded to the members at least 14 days prior to the time of the General Aswsembly.

The Society can only be dissolved if such decision is made at the General Assembly by more than 2/3 of the votes given by the members present.  If less than 2/3 of the members of the  society are present an extraordinary General assembly must be summoned and at least 2/3 of the members present on this occasion must vote for the decision. 

In case the Society is dissolved it is the responsibility of the Board to decide how to manage the capital of the Society.